STOCK MARKET UPDATE

Ticker

6/recent/ticker-posts

DCGI grants Emergency Use Authorisation to Covid vaccine Corbevax for children between 12-18 years of age

 Tweeted by @AIR

 Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation to COVID-19 vaccine Corbevax for children between 12-18 years of age group. The vaccine has been developed by Hyderabad-based pharmaceutical company Biological E Ltd which country's  first indigenously developed Receptor Binding Domain protein sub-unit COVID-19 vaccine. 

Earlier, the vaccine had received emergency use authorisation for the adult population in December last year. The Corbevax vaccine is administered through an intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degree Celsius temperature.

Talking to AIR News, Member, Health, NITI Aayog Dr VK Paul said, with the emergency use approval to Corbevax, the country has now two Covid-19 vaccines for children including Covaxin which is already in use for the children aged 15 to 18 years.

 

Social media is bold.


Social media is young.

Social media raises questions.

 Social media is not satisfied with an answer.

Social media looks at the big picture.

 Social media is interested in every detail.

social media is curious.

 Social media is free.

Social media is irreplaceable.

But never irrelevant.

Social media is you.

(With input from news agency language)

 If you like this story, share it with a friend!  


We are a non-profit organization. Help us financially to keep our journalism free from government and corporate pressure

 

Post a Comment

0 Comments

Custom Real-Time Chart Widget

'; (function() { var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true; dsq.src = '//' + disqus_shortname + '.disqus.com/embed.js'; (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(dsq); })();

market stocks NSC